N/A N=252 Sleep Apnea in TIA/Stroke: Reducing Cardiovascular Risk With Positive Airway Pressure
Transient Ischemic Attack · Stroke
Primary: HOMA IR Change From Baseline — 0.9; 4.0; 4.1 HOMA-IR Index
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 68Ga-PSMA-R2 in Patients With Biochemical Relapse (BR) and Metastatic Prostate Cancer (mPCa)
Prostate Cancer Metastatic
Primary: Number of Participants With Treatment Emergent Adverse Events — 1; 4; 2; 0 Participants
N/A N=10 Monitoring Medication Adherence in Left Ventricular Assist Device Recipients
Heart Failure · Medication Compliance
Primary: System Performance - Positive Detection Accuracy — 80 percentage of ingestions
N/A N=45 Non-Invasive Reduction of Fat in the Inner Thighs
Body Fat Disorder
Primary: Percentage of Pre-Treatment Images Correctly Identified by Reviewers — 90.5 percentage of correct identifications
N/A N=155 Sex and Age Ultrasound Response to Differential Jugular Vein Pressure
Concussion, Mild
Primary: Neck Collar Size — 11.15; 11.11; 11.25; 11.21 inches
Phase 3 N=607 An Open-Label, Long-Term Extension Study to Evaluate the Safety of CB-03-01 Cream, 1% in Participants With Acne Vulgaris
Acne Vulgaris
Primary: Number of Participants With Any Local and Systemic Treatment Emergent Adverse Events — 58; 52 Participants
Phase 3 N=32 Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia
Nocturia
Primary: Serum Sodium Levels at Baseline and During Treatment — 141.0; 140.0; 139.2; 140.3 mmol/L
N/A N=174 Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)
Glaucoma
Primary: Change From Baseline in Mean Intraocular Pressure (IOP) to 36 Months After Implantation — 21.03; 20.21; -6.42; -6.73 mm Hg — p=<.0001
N/A N=36 Treatment Intensity - Apraxia of Speech
Aphasia · CVA · Apraxia of Speech
Primary: Accuracy of Articulation of TREATED ITEMS Measured as Effect Size - Change From Baseline to End of Treatment Phase — 19.7; 28.9 effect sizes; magnitude of change — p=.0128
Phase 4 N=22 Efficacy of Resveratrol in Depression
Depression
Primary: Change in Total HDRS-17 Score From Baseline to Week 4 — -7.2; -9.9 score on a scale
Phase 2 N=150 A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema
Diabetic Macular Edema
Primary: Mean Change in Vision at 24 Months — 72.5; 75.0; 75.0 units on a scale
N/A N=35 Evaluation of Tangible Boost Replenishing System
Contact Lens Solution
Primary: Number of Patients With Adverse Event Reports or Discontinuations — 4; 2; 4 Participants
N/A N=120 The Effect of Lubricating Gel on Patient Comfort During Speculum Insertion.
Examination, Gynecological · Examination, Pelvic · Examination, Vaginal
Primary: Patient Discomfort During Speculum Insertion as Measured by a Visual Analog Scale. — 1.41; 2.15 score on a scale
Phase 2 N=24 Local Infusion of Ropivacaine for Post-Op Pain Control After Osseocutaneous Free Flaps
Head and Neck Cancer · Free Tissue Transfer
Primary: Post-Operative Pain at Donor-Site — 52.40; 41.14; 41.00; 40.88 score on a scale
N/A N=31 Study of Treatment for Opioid Dependence and Anxiety Disorders
Anxiety Disorders · Opiate Addiction
Primary: Urine-confirmed Self-reported Weeks of Opioid Use — 1; .36; .31 weeks